Index Entries

Priyamadhaba Behera, Binod Kumar Patro, Arvind Kumar Singh, Pradnya Dilip Chandanshive, Ravikumar S. R., Somen Kumar Pradhan, Siva Santosh Kumar Pentapati, Gitanjali Batmanabane, Prasanta Raghab Mohapatra, Biswa Mohan Padhy, Shakti Kumar Bal, Sudipta Ranjan Singh, and Rashmi Ranjan Mohanty
February 16, 2021
PLOS One
All India Institute of Medical Sciences Bhubaneswar (India)

Background: Ivermectin is one among several potential drugs explored for its therapeutic and preventive role in SARS-CoV-2 infection. The study was aimed to explore the association between ivermectin prophylaxis and the development of SARS-CoV-2 infection among healthcare workers…

Conclusion: Two-dose ivermectin prophylaxis at a dose of 300 μg/kg with a gap of 72 hours was associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the following month. Chemoprophylaxis has relevance in the containment of pandemic.”

document
COVID-19,ivermectin,medical treatments,pharmaceuticals